Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes by Islam Alfreahat MS, Hamdi Nsairat PhD, Ibrahim Deeb Aldeeb PhD, Ali Al-Samydai PhD, Walhan Alshaer PhD

“…This approach may offer a promising strategy to overcome DOX resistance and improve chemotherapy outcomes.…”
Get full text

Targeting lipid metabolism: novel insights and therapeutic advances in pancreatic cancer treatment by Yanyan Zhang, Zhichao Yang, Yuchen Liu, Jinjin Pei, Ruojie Li, Yanhui Yang

“…Standard treatments for PC such as surgical resection, chemotherapy, and radiotherapy. However, these therapies often face significant challenges, including biochemical recurrence and drug resistance. …”
Get full text

Effect of dendritic cell vaccine on blood redox status in patients with cervical cancer by A. P. Menshenina, I. A. Goroshinskaya, E. M. Frantsiyants, T. I. Moiseenko, E. V. Verenikina, I. V. Kaplieva, L. A. Nemashkalova

“…Levels of malondialdehyde (MDA), reduced glutathione and antioxidant enzyme activity were studied in 27 patients aged 27–65 years with advanced primary and recurrent CC receiving chemotherapy (CT) with DCV or DCV as monotherapy at a dose of 10 million cells intradermally once a week. …”
Get full text

Revolutionizing radiotherapy: gold nanoparticles with polyphenol coating as novel enhancers in breast cancer cells—an in vitro study by Simona Tarantino, Annalisa Bianco, Mariafrancesca Cascione, Alessandra Carlà, Lia Fiamà, Riccardo Di Corato, Livia Giotta, Paolo Pellegrino, Anna Paola Caricato, Rosaria Rinaldi, Valeria De Matteis

“…Standard treatments like chemotherapy and radiotherapy, often used after mastectomy, show varying effectiveness based on the cancer subtype. …”
Get full text

Acute Coronary Syndrome in Acute Myeloid Leukemia with Maturation Accompanying Megakaryocytic Differentiation by Kentaro Odani, Junya Abe, Yoshiaki Tsuyuki, Soshi Yanagita, Kazuya Shiogama, Mitsuhiro Tachibana, Yutaka Tsutsumi

“…Even after emergent percutaneous coronary intervention, his performance status remained poor, so no chemotherapy against leukemia was given. The final white blood cell count reached 291,700/μL, and the platelet count was elevated to 510,000/μL. …”
Get full text

Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN by Yuan Zeng, Haoran Jiang, Zhoufeng Chen, Jun Xu, Xiangting Zhang, Weimin Cai, Xianjie Zeng, Peipei Ma, Rong lin, Huilin Yu, Yuanhang He, Huiya Ying, Ruoru Zhou, Xiao Wu, Fujun Yu

“…This study elucidates a shared mechanism underlying OXA and 5-Fu resistance in hepatocellular carcinoma and highlights a promising therapeutic target for overcoming clinical chemotherapy resistance.…”
Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

“…Patients with DLBCL (vs HGBCL), complete response before infusion, prior autologous or allogeneic haematopoietic stem cell transplant and lactate dehydrogenase (LDH) within normal limits experienced more favourable efficacy outcomes, and those with Eastern Cooperative Oncology Group performance status of ≥2, ≥3 prior lines of therapy, elevated LDH and fludarabine-based lymphodepleting chemotherapy experienced less favourable safety outcomes.Conclusions This real-world study of tisagenlecleucel for patients with R/R DLBCL/HGBCL shows consistent efficacy and better safety outcomes than the pivotal trial. …”
Get full text

Insight into the current practice of ototoxicity monitoring during cisplatin therapy by N. M. Santucci, B. Garber, R. Ivory, M. A. Kuhn, M. Stephen, D. Aizenberg

“…Abstract Background The aim of this study is to evaluate the current state of ototoxicity monitoring for patients receiving cisplatin chemotherapy in an academic medical center with particular attention to how closely monitoring adheres to national ototoxicity guidelines. …”
Get full text

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV s... by Muhit Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas

“…Previous studies reported higher rates of post– hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. It is unknown if a lower InO dose would reduce risk of post-HSCT SOS or if it would impact efficacy. …”
Get full text

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP by Tomohiro Kadota, Sachiko Seo, Hiroe Fuse, Genichiro Ishii, Kuniaki Itoh, Tomonori Yano, Kazuhiro Kaneko, Kunihiro Tsukasaki

“…Abstract Standard therapy for gastric diffuse large B‐cell lymphoma (DLBCL) is considered to be chemotherapy with or without involved‐field radiation therapy. …”
Get full text

Prehospital care for ovarian cancer in Catalonia: could we do better in primary care? Retrospective cohort study by Mercè Marzo-Castillejo, Josep M Borras, Carmen Vela-Vallespín, Paula Manchon‐Walsh, Luisa Aliste

“…Survival was not associated with a starting point involving primary care (HR 1.39, 95% CI 0.93 to 2.09), diagnostic pathways involving referral to elective gynaecological care from non-general practitioners (HR 0.80, 95% CI 0.51 to 1.26), or self-presentation to emergency services (HR 0.82, 95% CI 0.52 to 1.31).Conclusions Survival in EOC is not associated with diagnostic pathways or prehospital healthcare, but it is influenced by stage at diagnosis, administration of primary cytoreduction plus chemotherapy and patient age.…”
Get full text

Enhancing Perioperative Outcomes of Pancreatic Surgery with Wearable Augmented Reality Assistance System: A Matched-Pair Analysis by Hamraz Javaheri, MSc, Omid Ghamarnejad, MD, Rizky Widyaningsih, MD, Ragnar Bade, PhD, Paul Lukowicz, PhD, Jakob Karolus, PhD, Gregor Alexander Stavrou, MD

“…A higher proportion of patients in the ARAS group were diagnosed with borderline resectable pancreatic cancer and received neoadjuvant chemotherapy (20.0% vs 6.7%, P = 0.085). Additionally, more patients in the ARAS group required arterial resection compared with the control group (15.0% vs 0.0%, P = 0.002). …”
Get full text

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era by Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, Mark S. Walker, Yanina Natanzon

“…Growing evidence indicates surgery with adjuvant or neoadjuvant chemotherapy (SC) may be superior to non-surgical treatments. …”
Get full text

Progress and application of intelligent nanomedicine in urinary system tumors by Yingming Xiao, Lei Zhong, Jinpeng Liu, Li Chen, Yi Wu, Ge Li

“…Furthermore, the therapeutic applications of intelligent nanomedicine, its advantages over traditional chemotherapy, and the challenges currently facing clinical translation of nanomedicine, such as safety, regulation and scalability, have also been reviewed. …”
Get full text

NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration by Youlong Zhu, Zongze Qi, Shaoqi Zu, Fangchao Yang, Yanming Wang, Lei Zhu, Xintong Li, Ruixue Li, Hong Zhu

“…The Genomics of Drug Sensitivity in Cancer (GDSC) database was utilized to investigate the relationship between NIPAL1 expression and the efficacy of common drugs used in chemotherapy and targeted therapy in patients with pancreatic cancer. …”
Get full text

Mucin-producing urothelial-type adenocarcinoma of the prostate with a gene mutation characteristic of intestinal adenocarcinoma: case report and literature review by Ao Yu, Ao Yu, Hongbo Su, Peiling Yu, Siqi Cai, Shuaixian Mu, Jinhui Yu, Qianting Lu, Yuan Miao, Ailin Li

“…NGS is recommended for patients with MPUAP, and regarding chemotherapy, treatment options for colorectal cancer are worth considering.…”
Get full text

Management of the Uncommon Bladder Cancers: A Single-Center Experience over 10 Years by Youssef Kadouri, Salim Lachkar, Hamza Dergamoun, Hachem El Sayegh, Lounis Benslimane, Yassine Nouini

“…Our patients were managed by a wide range of therapeutic modalities as total cystectomy with bilateral lymph node dissection (63%), palliative chemotherapy (30%), or concomitant radiochemotherapy (7%). 55.6% of patients were alive one year after diagnosis. …”
Get full text

Pleuroparenchymal Fibroelastosis: A New Entity within the Spectrum of Rare Idiopathic Interstitial Pneumonias by Karina Portillo, Ignasi Guasch, Caroline Becker, Felipe Andreo, Maria Teresa Fernández-Figueras, José Ramirez Ruz, Carlos Martinez-Barenys, Samuel García-Reina, Pedro Lopez de Castro, Irene Sansano, Ana Villar, Juan Ruiz-Manzano

“…The etiology of the disease is unclear, although some cases have been associated as a complication after bone marrow transplantation, lung transplantation (LT), chemotherapy, and recurrent respiratory infections. The patients usually report progressive dyspnea and dry cough and are predisposed to develop spontaneous or iatrogenic pneumothoraces after surgical lung biopsy (SLB) for its diagnosis. …”
Get full text

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy by Nao Kobayashi, Noriaki Sunaga, Masakiyo Yatomi, Ikuo Wakamatsu, Sohei Muto, Hayato Ikota, Rei Yamaguchi, Yoichi Ohtaki, Toshiteru Nagashima, Nobuteru Kubo, Tomomi Masuda, Yosuke Miura, Hiroaki Tsurumaki, Reiko Sakurai, Yasuhiko Koga, Takeshi Hisada, Toshitaka Maeno

“…He subsequently received platinum‐based chemotherapy with durvalumab, resulting in sustained regression of the liver metastases. …”
Get full text

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACO... by David Malka, Philippe Laramée, Mondher Toumi, Jean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, Dan Howard, Andy Buckland, Marine Sivignon, Emilie Clay, Emmanuelle Samalin

“…Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FOLFIRI (folinic acid, fluorouracil and irinotecan) or irinotecan). …”
Get full text